A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes. POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)

0Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Objectives: The aim of this study was to clarify whether pioglitazone suppresses in-stent neointimal proliferation and reduces restenosis and target lesion revascularization (TLR) after percutaneous coronary intervention (PCI). Background: Previous single-center studies have demonstrated the anti-restenotic effect of a peroxisome proliferator-activated receptor gamma agonist, pioglitazone, after PCI. Methods: A total of 97 patients with type 2 diabetes mellitus (T2DM) undergoing PCI (bare-metal stents only) were enrolled. After PCI, patients were randomly assigned to either the pioglitazone group (n = 48) or the control group (n = 49). Angiographical and intravascular ultrasound (IVUS) imaging were performed at baseline and repeated at 6-month follow-up. Primary end points included angiographical restenosis and TLR at 6 months follow-up. Secondary end point was in-stent neointimal volume by IVUS. Results: Baseline glucose level and glycosylated hemoglobin (HbA1c) level were similar between the pioglitazone group and the control group. Angiographical restenosis rate was 17% in the pioglitazone group and 35% in control group (p = 0.06). The TLR was significantly lower in pioglitazone group than in control group (12.5% vs. 29.8%, p = 0.04). By IVUS (n = 56), in-stent neointimal volume at 6 months showed a trend toward smaller in the pioglitazone group than in the control group (48.0 ± 30.2 mm3 vs. 62.7 ± 29.0 mm3, p = 0.07). Neointimal index (neointimal volume/stent volume × 100) was significantly smaller in the pioglitazone group than in the control group (31.1 ± 14.3% vs. 40.5 ± 12.9%, p = 0.01). Conclusions: Pioglitazone treatment might suppress in-stent neointimal proliferation and reduce incidence of TLR after PCI in patients with T2DM. © 2009 American College of Cardiology Foundation.

Cite

CITATION STYLE

APA

Takagi, T., Okura, H., Kobayashi, Y., Kataoka, T., Taguchi, H., Toda, I., … Yoshikawa, J. (2009). A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes. POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC: Cardiovascular Interventions, 2(6), 524–531. https://doi.org/10.1016/j.jcin.2009.04.007

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free